Attached files
| file | filename |
|---|---|
| EX-32.2 - AIM ImmunoTech Inc. | ex32-2.htm |
| EX-32.1 - AIM ImmunoTech Inc. | ex32-1.htm |
| EX-31.2 - AIM ImmunoTech Inc. | ex31-2.htm |
| EX-31.1 - AIM ImmunoTech Inc. | ex31-1.htm |
| EX-21 - AIM ImmunoTech Inc. | ex21.htm |
| EX-10.59 - AIM ImmunoTech Inc. | ex10-59.htm |
| EX-10.58 - AIM ImmunoTech Inc. | ex10-58.htm |
| EX-10.57 - AIM ImmunoTech Inc. | ex10-57.htm |
| EX-10.48 - AIM ImmunoTech Inc. | ex10-48.htm |
| EX-10.47 - AIM ImmunoTech Inc. | ex10-47.htm |
| EX-10.46 - AIM ImmunoTech Inc. | ex10-46.htm |
| EX-10.45 - AIM ImmunoTech Inc. | ex10-45.htm |
| EX-4.8 - AIM ImmunoTech Inc. | ex4-8.htm |
| 10-K - AIM ImmunoTech Inc. | form10-k.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (No. 333-118903, 333-155528, 333-160499, 333-209060, and 333-220296) on Form S-8, Registration Statement (No. 333-205228 ) on Form S-3, and Registration Statement (No. 333-217671 and 333-220756) on Form S-1 of Hemispherx Biopharma, Inc. and subsidiaries of our report dated March 30, 2018, relating to the consolidated financial statements of Hemispherx Biopharma, Inc., appearing in this Annual Report on Form 10-K of Hemispherx Biopharma, Inc. for the year ended December 31, 2017.
|
/s/ RSM US LLP |
|
| RSM US LLP | |
|
Blue Bell, Pennsylvania |
|
| March 30, 2018 |